#ESMO26 New data on biomarker efficacy for #cMET #ADCs in both #EGFR WT and #EGFR mut pretreated patients:
➡️ IHC MET cut-off at 10% +++ for TemabA
➡️ Magnitude of benefit correlated with MET IHC for EGFR WT but was similar for
EGFRmut NSCLC
➡️Comparative efficacy of TemabA to Trop2 targeting ADCs
@myESMO #ESMOAmbassadors
32 浏览 · 1 赞 · 0 转发 · 0 回复
Improving prevention of moderate to severe dermatologic adverse events in EGFR-mutant advanced NSCLC treated with first-line (1L) subcutaneous (SC) amivantamab + lazertinib: First results from a new COCOON cohort
https://esmocongress.esmo.orgExtended circulating tumor DNA (ctDNA) sequencing to optimize the selection between anti-EGFR rechallenge and other later lines in patients with RAS/BRAF wild-type metastatic colorectal cancer
https://esmocongress.esmo.org- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
https://esmocongress.esmo.org来源：Giannis Mountzios · x.com